Page last updated: 2024-11-06

tallimustine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

tallimustine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65924
CHEMBL ID89705
SCHEMBL ID62279
MeSH IDM0183547

Synonyms (17)

Synonym
CHEMBL89705
tallimustine
n''-(2-amidinoethyl)-4-(p-(bis(2-chloroethyl)amino)benzamido)-1,1',1''-trimethyl-n,4':n',4''-ter(pyrrole-2-carboxamide)
tallimustine [inn]
n'-(2-amidinoethyl)-4-(p-(bis(2-chloroethyl)amino)benzamido)-1,1',1'-trimethyl-n,4':n',4'-ter(pyrrole-2-carboxamide)
1h-pyrrole-2-carboxamide, n-(5-(((3-amino-3-iminopropyl)amino)carbonyl)-1-methyl-1h-pyrrol-3-yl)-4-(((4-((4-(bis(2-chloroethyl)amino)benzoyl)amino)-1-methyl-1h-pyrrol-2-yl)carbonyl)amino)-1-methyl-
n-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-[[4-[bis(2-chloroethyl)amino]benzoyl]amino]-1-methylpyrrole-2-carboxamide
115308-98-0
unii-71193oxg6s
71193oxg6s ,
SCHEMBL62279
DTXSID40151045
1h-pyrrole-2-carboxamide, n-[5-[[(3-amino-3-iminopropyl)amino]carbonyl]-1-methyl-1h-pyrrol-3-yl]-4-[[[4-[[4-[bis(2-chloroethyl)amino]benzoyl]amino]-1- methyl-1h-pyrrol-2-yl]carbonyl]amino]-1-methyl-
DB15466
Q27265910
CS-0025562
HY-105270

Research Excerpts

Overview

Tallimustine (FCE 24517) is an AT-specific alkylating antitumor derivative of distamycin.

ExcerptReferenceRelevance
"Tallimustine is a novel benzoyl mustard derivative from distamycin A with a unique mode of action. "( Tallimustine in advanced previously untreated colorectal cancer, a phase II study.
Corradino, I; Dirix, LY; Humblet, Y; Polli, A; Punt, CJ; Roca, E; Wainstein, R, 1996
)
3.18
"Tallimustine (FCE 24517) is an AT-specific alkylating antitumor derivative of distamycin. "( Tallimustine lesions in cellular DNA are AT sequence-specific but not region-specific.
Arnett, B; Herzig, MC; Trevino, AV; Woynarowski, JM, 1999
)
3.19

Toxicity

ExcerptReferenceRelevance
" Comparing the different progenitor cell response to FCE 24517, canine CFU-gm and CFU-e were 26- to 221-fold more sensitive to this drug's toxic effects than their human and murine counterparts."( Comparative in vitro myelotoxicity of FCE 24517, a distamycin derivative, to human, canine and murine hematopoietic progenitor cells.
Du, DL; Mongelli, N; Murphy, MJ; Volpe, DA; Zurlo, MG, 1992
)
0.28

Pharmacokinetics

ExcerptReferenceRelevance
" Detailed pharmacokinetic blood sampling was performed during the first 3 days of the first course of tallimustine."( A phase I and pharmacokinetic study of tallimustine [PNU 152241 (FCE 24517)] in patients with advanced cancer.
DeMaria, D; Mooneyham, T; O'Dwyer, P; Patricia, E; Poggesi, I; Reilly, D; Rocchetti, M; Vitek, LV; Von Hoff, DD; Weiss, GR; Whaley, F, 1998
)
0.78

Dosage Studied

ExcerptRelevanceReference
" We found that the dose-response curves for tallimustine on BM and hCB cells were similar."( Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells.
Bosshard, G; Capolongo, L; Cavalli, F; D'Incalci, M; Geroni, MC; Ghielmini, M; Pesenti, E; Sessa, C; Torri, V, 1997
)
0.56
" Patients were treated at six dosage levels of 33."( A phase I and pharmacokinetic study of tallimustine [PNU 152241 (FCE 24517)] in patients with advanced cancer.
DeMaria, D; Mooneyham, T; O'Dwyer, P; Patricia, E; Poggesi, I; Reilly, D; Rocchetti, M; Vitek, LV; Von Hoff, DD; Weiss, GR; Whaley, F, 1998
)
0.57
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID98577Cytotoxicity was determined after 48 hr of continuous exposure against L1210 murine leukemia cells2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners.
AID88790The myelotoxicity was tested in vitro on human granulocyte macrophage colony forming units (CFU-GM) cord blood derived hematopoietic cells (1 hr exposure)2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners.
AID89265Cytotoxicity was determined after 1 hr exposure against six different human tumor cells lines2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners.
AID97133Ratio between IC50 values on L1210 and L1210/L-PAM cells2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners.
AID98578Cytotoxicity was determined after 48 hr of continuous exposure against L1210 murine leukemia cells,(cells resistant to melphalan (L-PAM)2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners.
AID90917Ratio between IC50 on human bone marrow progenitors (CFUGM) and tumor cells.2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (57)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's46 (80.70)18.2507
2000's10 (17.54)29.6817
2010's1 (1.75)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.61 (24.57)
Research Supply Index4.20 (2.92)
Research Growth Index4.19 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (10.00%)5.53%
Reviews3 (5.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other51 (85.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]